Summary Epidermal growth factor receptors (EGFr) were measured using a radioligand binding assay, in membrane preparations from 51 human non-small cell lung cancers and in normal tissue of the same patients.
16.4 fmol mgI of protein; range, 1.5-176) were significantly higher than in normal tissues (median, 7.4 fmol mg-' of protein; range, 1.9-13.4).
The receptor levels in normal tissue were normally distributed. It was therefore possible to define a normal/pathologic cut-off level (12.9 fmol mg-' of protein). In 57% of cases EGFr in cancer was higher than the cut-off. No relationships were found between receptor concentrations and positivity rates of EGFr and histology, stage, lymph node positivity and pT. A trend for a direct relation between receptor positivity and grading was found.
Epidermal Growth Factor receptor (EGFr) is a 170,000-Da transmembrane glycoprotein with an intracellular domain that contains intrinsic tyrosine kinase activity (Carpenter, 1983; Gill et al., 1987) . The enzymatic activity stimulated by EGF binding is directed against several protein substrates and the receptor itself (Hunter & Cooper, 1981; Cooper et al., 1982; Downward et al., 1984) , and result in regulating the growth and differentiation of many ectodermal-derived cells (Carpenter & Cohen, 1979) .
Some evidences suggest that EGFr could be related to malignant transformation. Indeed, transforming growth factor alpha (TGF(x), a peptide produced by transformed cells, was shown to stimulate the growth of malignant tissues through binding to the EGFr (Reynolds et al., 1981; Nickell et al., 1983) . EGFr sequence is related to erb-B2 oncogen product, a membrane protein with receptor function, and to v-erbB product, which represents the intracellular domain of EGFr.
Many studies show that EGFr may play a role in the development of different ectodermal-derived malignancies. High concentrations of EGFr were found in tumours of the nervous system (Libermann et al., 1984) , bladder (Neal et al., 1985) and head and neck (Ishitoya et al., 1989) . High levels of EGFr in breast cancer have been related to a poorer prognosis (Sainsbury et al., 1987) .
The presence of EGFr in lung cancer has been reported in non-small cell lung cancer (NSCLC) tissue samples (Berger et al., 1987; Cerny et al., 1986; Dazzi et al., 1989; Hendler & Ozanne, 1984; Sobol et al., 1987; Hwang et al., 1986; Veale et al., 1987; Veale et al., 1989) . The absence of the EGFr (Hendler & Ozanne, 1984; Sobol et al., 1987) and EGFr gene expression (Gamou et al., 1987) (Berger et al., 1987; Cerny et al., 1986; Dazzi et al., 1989; Veale et al., 1987; Veale et al., 1989) .
EGFr concentration was found to be higher in cancer than in normal lung tissue. However, the analysis of EGFr in normal lung samples was so far performed only in a limited number of cases (Hwang et al., 1986; Veale et al., 1987; Veale et al., 1989 (UICC, 1979) . Histologic typing was performed following WHO criteria (WHO, 1981) . Sample of both tumour tissue and apparently normal lung tissue, at least 10 cm apart from the tumour, were collected freshly at the time of operation from each patient.
Samples were washed several times with cold isotonic saline solution (4°C), minced, quick frozen, and stored in liquid nitrogen.
Procedures
Membrane preparation and EGFr assay were performed as previously described (Dittadi et al., 1990) . Supercooled tissue samples were pulverised, homogenised in Tris buffer and centrifuged at 800 g for 10 min at 4°C. The pellet was washed twice more and the supernatants pooled and centrifuged at 100,000g for 1 h at 4°C. The membrane pellet was incubated with 0.5 nm final concentration of human '25I-EGF prepared by lactoperoxidase method (S.A. 1,000-1,400 Ci mmolP ' Amersham, UK). The concentration used for the binding analysis ranged from 6 to 0.06 nm. The determination of non-specific binding was performed by using cold human EGF (Amersham) at a concentration 100 time the maximal '251I-EGF dose. The mixture was incubated 20 h at 260C, centrifuged at 5,000g for 30min, the supernatant was discarded and the pellet was counted in a T-counter.
The total protein concentration was measured by the Bradford protein-dye binding method (Bradford, 1976 In normal lung tissue the concentrations of EGFr are normally distributed (Figure 2) (Table III) . A trend for a direct relation between receptor positivity and grading were found (Table III) The number of normal lung tissue evaluated in the present study is higher than the total number of cases reported in so far published studies (Hwang et al., 1986; Veale et al., 1987; Veale et al., 1989) . It was therefore possible to compare both the binding characteristics and the distribution of EGFr concentrations between cancer and normal tissue using a number of cases adequate for statistical evaluation.
The binding characteristics of EGFr were similar in normal tissue and in cancer, showing a presence of two binding sites with different affinities, as previously noted both in cell cultures (Schlessinger, 1988; King & Cuatrecasas, 1982) and in lung tissues (Veale et al., 1989) .
From the binding studies we could determine the 1251I-EGF concentration capable of saturating the high affinity sites (0.5 nM), which can be used in a single saturating dose assay when small tissue samples are available.
In the cancer tissue receptor levels (range 1.5-176 fmol mg' of protein) are higher than in normal lung (range 1.9-13.4 fmol mg'-of protein). These findings confirm preliminary observations reported by Hwang et al. (1986) on six cases, by Veale et al. (1987) on 17 cases and by Veale et al. (1989) on eight cases. In 80% of cases the concentrations in cancer are higher than in the normal tissue from the same patient. Considering that EGFr concentrations were found to be very high in fetal lung (Nexo & Kryger-Baggesen, 1989) , the increased expression of EGFr in lung cancer could be a consequence of tissue dedifferentiation, and could regulate the tumour growth by an autocrine mechanism. The distribution pattern in normal lung tissue was Gaussian, suggesting that EGFr in lung tissue could be physiologically expressed. This finding allows for the calculation of a normal/pathologic cut-off point that could be used to classify cancer samples even when the normal tissue is not available.
We did not find significant differences in EGFr concentrations between squamous cell carcinomas, adenocarcinomas and large cell carcinomas, which is in agreement with the previous studies carried out with binding methods (Hwang et al., 1986; Veale et al., 1989) . Instead, immunohistochemical studies report conflicting results. Hendler et al. (1984) found EGFr only in squamous cell carcinomas. Other authors found EGFr in all the NSCLCs, with higher concentrations in squamous carcinomas (Berger et al., 1987; Sobol et al., 1987; Veale et al., 1987) or without significative differences between histological types (Cerny et al., 1986; Dazzi et al., 1989) . However, immunohistochemical methods do not allow for a precise quantification and, in particular for EGFr, seems to be less sensitive to binding saturation assays (Sobol et al., 1987; Veale et al., 1989) .
The attempt to establish the relationships between EGFr and other known prognostic factors led to conflicting results. Higher concentrations in stage III tumours have been found (Veale et al., 1987) , but these results were not confirmed by the same authors in a following report carried out by a saturation binding assay (Veale et al., 1989) . Dazzi et al. (1989) , in a retrospective study performed by immunohistochemical method, found a higher expression of EGFr in well differentiated tumour.
However, the EGFr positivity was so far established on the basis of the sensitivity of assays or semiquantitative classifications.
In this study, the finding of Gaussian distribution in normal tissue allowed us to define the EGFr positivity in lung cancer on the basis of a physiologically and statistically acceptable cut-off point. No relationships were found between EGFr concentrations or positivity rates and the prognostic parameters evaluated. A possible independent prognostic role of EGFr could be therefore postulated.
